Skip adjuvant chemo after gastric cancer surgery
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether skipping chemotherapy after surgery is safe and effective for some patients with gastric cancer. If your tumor responded very well or very poorly to the pre-surgery chemotherapy, you might be able to avoid more chemo.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stomach cancer (adenocarcinoma) that was not stage IV at diagnosis.
- You completed the planned chemotherapy before surgery (neoadjuvant chemotherapy).
- You had surgery to remove the tumor, and it was within the last 12 weeks.
- Your tumor is NOT HER2-positive or MSI/dMMR positive.
- After surgery, the tumor response was either TRG1 (with no lymph node spread) or TRG4-5.
- You are in good general health (ECOG 0-1) with adequate blood counts and liver function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two chemotherapy combinations given before surgery for stomach cancer that has not spread. The goal is to see which treatment works better and to shrink the tumor before removal.
This trial tests if surgery to remove the stomach and some tumors, after a few months of chemo, helps people whose stomach cancer has spread to only a few nearby spots (like the lining of the belly, liver, or lymph nodes) live longer compared to chemo alone.
This trial tests a minimally invasive surgery for stomach cancer that has spread to lymph nodes near the main blood vessels (para-aortic area). The surgery is done after a combination of chemotherapy and immunotherapy to shrink the tumor. It aims to see if this approach is safe and effective.
This trial tests a combination of chemotherapy drugs given before surgery for locally advanced stomach or gastroesophageal junction cancer. It aims to see if this approach helps shrink the tumor and improve outcomes.
This study looks for ways to predict whether neoadjuvant chemotherapy (chemo given before surgery) will work well in people with locally advanced stomach cancer. It may help doctors choose the best treatment plan sooner based on your test results.
This Phase 3 trial studies whether adding an immune medicine called PD-1 (given as an “inhibitor”) to standard chemotherapy and chemoradiation after stomach/GEJ cancer surgery can lower the risk of cancer coming back. You may qualify if you’ve had surgery removing the tumor and lymph nodes showed higher-risk disease.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.